This volume reviews advances in cancer chemotherapy research over the last 10 years. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs. Each chapter covers the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.
This volume reviews advances in cancer chemotherapy research over the last 10 years. Chapters written by leading experts in their field reflect a range of current medicinal chemistry approaches to small molecule drugs. Each chapter covers the drug target and biological rationale, chemotypes, clinical status and future prospects in this rapidly developing area of drug research.
Overview.- Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer.- Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK.- Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic.- Survival Signaling.- Progress in the Development of Agents to Control the Cell Cycle.- HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit.- Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy.- Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy.- Bcr-Abl Kinase Inhibitors.
Overview.- Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer.- Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK.- Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic.- Survival Signaling.- Progress in the Development of Agents to Control the Cell Cycle.- HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit.- Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy.- Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy.- Bcr-Abl Kinase Inhibitors.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826